5-day radiation therapy before surgery for soft tissue sarcomas
Official title: Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
Run by Jonsson Comprehensive Cancer Center · NCT02701153 · Data updated 2026-11-12
This study is testing if a shorter, stronger course of radiation therapy before surgery can help people with recurring soft tissue sarcomas do better and have fewer side effects.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 51 (estimated) |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Los Angeles, California) |
| Status | Recruiting |
| Started | February 3, 2016 |
| Main results expected | February 3, 2027 |
| Study ends | February 3, 2028 |
| Registry record updated | March 10, 2026 |
| Trial ID | NCT02701153 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with histologically confirmed, resectable soft tissue sarcomas of intermediate or high grade, particularly those who have not received prior radiation therapy.
✕Probably not a fit
Patients with active treatment for another malignancy or a history of prior irradiation to the treatment area may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase II trial evaluates the effects of hypofractionated radiation therapy on patients with recurrent adult soft tissue sarcomas prior to surgical intervention. The approach involves delivering higher doses of radiation over a shorter time frame, which may enhance tumor cell destruction while minimizing side effects. The study aims to assess radiation-related morbidity, local and regional control of the disease, and overall survival rates, alongside functional outcomes and genetic factors influencing cancer predisposition. Patients will receive radiation therapy for five consecutive days, followed by surgery 2-12 weeks later, with follow-up assessments conducted for five years.
Why it matters
Potential benefit: If successful, this treatment could improve surgical outcomes and reduce side effects for patients with soft tissue sarcomas.
How similar studies have gone: Other studies have shown promise with hypofractionated radiation therapy approaches, suggesting potential for success in this novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed soft tissue sarcoma of the extremity/trunk * Intermediate or high grade sarcoma * Resectable primary lesion (patients with pre-existing metastasis will be included if their primary is still going to be resected) * Recurrent, any grade, no previous radiation therapy * Karnofsky performance status (KPS) \>= 70 or Eastern Cooperative Oncology Group (ECOG) 0 - 2 * If a woman is of childbearing potential, a negative serum pregnancy test must be documented Exclusion Criteria: * Active treatment of a separate malignancy * History of prior irradiation to the area to be treated * Pre-operative chemotherapy (post-op acceptable)
Where it's running
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States Recruiting
Study contacts
- Principal investigator: Anusa Kalbasi, MD — UCLA / Jonsson Comprehensive Cancer Center
- Study coordinator: Jackie Hernandez
- Email: jhernandez@mednet.ucla.edu
- Phone: 310-206-8477
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AB801 with chemotherapy and immunotherapy for cholangiocarcinoma and pancreatic cancer
This phase 1 study tests whether AB801 can be given safely with chemotherapy and immunotherapy in adults with border-line resectable, locally advanced, or metastatic cholangiocarcinoma or pancreatic cancer.
-
Triple-target radiosurgery for cancer pain using pituitary and thalamic neuromodulation
This study tests whether focused brain radiosurgery to the pituitary and specific thalamic regions can reduce pain in adults with cancer that’s not controlled by opioids or other treatments.
-
Focal HDR-Brachytherapy for Prostate Cancer
This trial tests using targeted high-dose-rate brachytherapy to treat prostate cancer patients and see if it provides local control with fewer side effects.
-
Using advanced MRI to image the tumor immune environment in glioblastoma
This project will test whether three advanced MRI methods (CEST, DR-CSI, and ferumoxytol-enhanced MRI) can noninvasively measure immune cells and proteins around glioblastoma tumors in adults preparing for surgery.
-
Individually Tailored, Supervised, Remote Exercise to Improve Function in Stage I-III Gastroesophageal Cancer Survivors
This trial tests a personalized, supervised home-based exercise program to see if it can improve physical function for adults who have completed treatment for early-stage gastroesophageal cancer.
-
Advanced MRI to distinguish recurrent brain tumor from radiation necrosis
This trial tests whether advanced MRI scans (DR-CSI and sodium imaging) can tell if people with metastatic brain tumors have tumor recurrence or treatment-related radiation necrosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.